Acorda Therapeutics Inc ACOR
We take great care to ensure that the data presented and summarized in this overview for ACORDA THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACOR
View allLatest Institutional Activity in ACOR
Top Purchases
Top Sells
About ACOR
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Insider Transactions at ACOR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 17
2023
|
Ron Cohen President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+6.26%
|
$0
$0.65 P/Share
|
|
Mar 16
2023
|
Ron Cohen President and CEO |
BUY
Open market or private purchase
|
Direct |
10,156
+6.77%
|
$0
$0.6 P/Share
|
|
Sep 03
2022
|
Lauren M Sabella Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,511
-12.36%
|
$0
$0.4 P/Share
|
|
Sep 03
2022
|
Kerry M Clem Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,511
-13.03%
|
$0
$0.4 P/Share
|
|
Mar 17
2022
|
Ron Cohen President and CEO |
SELL
Open market or private sale
|
Direct |
2,289
-1.74%
|
$2,289
$1.7 P/Share
|
|
Sep 03
2021
|
Ron Cohen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,940
-2.9%
|
$15,760
$4.38 P/Share
|
|
Sep 03
2021
|
Robert Morales Interim PAO & PFO |
SELL
Payment of exercise price or tax liability
|
Direct |
448
-9.2%
|
$1,792
$4.38 P/Share
|
|
Sep 03
2021
|
Lauren M Sabella Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,511
-11.0%
|
$6,044
$4.38 P/Share
|
|
Mar 03
2021
|
Burkhard Blank CMO and Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
11,125
+37.52%
|
-
|
|
Mar 03
2021
|
Ron Cohen President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
29,000
+17.59%
|
-
|
|
Mar 03
2021
|
Lauren M Sabella Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,125
+44.76%
|
-
|
|
Dec 01
2020
|
David Lawrence Chief, Bus. Ops & PAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,141
-7.63%
|
$0
$0.65 P/Share
|
|
Nov 09
2020
|
David Lawrence Chief, Bus. Ops & PAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,024
-6.41%
|
$0
$0.86 P/Share
|
|
Jan 30
2019
|
Scopia Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
7,000
-0.15%
|
$112,000
$16.01 P/Share
|
|
Jan 25
2019
|
Scopia Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,401
-0.05%
|
$38,416
$16.0 P/Share
|
|
Jan 24
2019
|
Scopia Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,600
-0.18%
|
$137,600
$16.03 P/Share
|
|
Jan 23
2019
|
Scopia Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
45,898
-0.95%
|
$734,368
$16.01 P/Share
|
|
Jan 22
2019
|
Scopia Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
51,945
-1.07%
|
$831,120
$16.02 P/Share
|
|
Jan 18
2019
|
Scopia Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
39,358
-0.8%
|
$629,728
$16.24 P/Share
|
|
Jan 17
2019
|
Scopia Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-2.0%
|
$1,600,000
$16.86 P/Share
|